New detalimogene bladder cancer data send the minnow’s stock up 47%.
ApexOnco Front Page
Recent articles
The response rate jumps to 30% with higher doses of IMA402.
Selectively hitting PARP1 is meant to reduce toxicity, and arguably the Petra trial shows this.
Fuelled with a $500m Summit windfall Akeso advances its lead bispecific.
When autogene cevumeran works it seems to keep working, but bigger tests for the project have been pushed back.
The group was a first mover in stage III NSCLC, and now it hopes to repeat the trick in SCLC.
The company looks rash for promising Tamarack data at the conference, although at least vobra duo’s safety has improved.
The company is setting up another battle with Bristol Myers Squibb, while Amgen has different plans.